bioprocess development

生物过程发展
  • 文章类型: Journal Article
    埃克托因,一种具有生物学意义的化合物,是由能够利用蔗糖的细菌菌株成功生产的。以一种突破性的方法,我们利用了甜菜糖蜜的潜力,一种富含蔗糖的副产品,氨基酸,和维生素,作为用于此目的的生长媒介。通过细致的调查,我们确定了理想的条件来最大化actoine合成。这一非凡的里程碑是通过每升只引入1克(炭黑NH)2SO4和5毫升糖蜜达到的,保持8.0的pH值,保持7.5%的NaCl浓度,采用120rpm搅拌,并保持30°C的温度。这项研究标志着一项开拓性的努力,因为它代表了通过Nesterenkoniasp。的种植有效地利用糖蜜生产etoine的第一个实例。我们展示了利用1L废糖蜜与这种特定的细菌菌株生产75.56g有价值的化合物ectoine。这些发现带来了巨大的希望,不仅在资源利用方面,而且在各种生物学环境中的etoine的潜在应用方面。
    Ectoine, a biologically significant compound, was successfully produced by a strain of bacteria capable of utilizing sucrose. In a ground-breaking approach, we harnessed the potential of sugar beet molasses, a by-product rich in sucrose, amino acid, and vitamins, as a growth medium for this purpose. Through meticulous investigation, we identified the ideal conditions for maximizing ectoine synthesis. This remarkable milestone was reached by introducing only 1 g of (NH₄)₂SO₄ and 5 mL of molasses per liter, maintaining a pH level of 8.0, upholding a 7.5% NaCl concentration, employing agitation at 120 rpm, and sustaining a temperature of 30 °C. This study marks a pioneering endeavour as it represents the first instance where molasses has been effectively employed to produce ectoine through the cultivation of Nesterenkonia sp. We showcased the production of 75.56 g of the valuable compound ectoine utilizing 1 L of waste molasses with this specific bacterial strain. These findings hold tremendous promise, not only in terms of resource utilization but also for the potential applications of ectoine in various biological contexts.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    现代机器学习有可能从根本上改变生物过程的发展方式。特别是,横向知识转移方法,寻求利用历史过程中的数据来促进新产品的过程开发,提供重新思考当前工作流程的机会。在这项工作中,我们首先评估两种知识转移方法的潜力,元学习和独热编码,结合高斯过程(GP)模型。我们将他们的表现与仅在新流程数据上训练的GP进行比较,也就是说,本地模型。使用模拟的哺乳动物细胞培养数据,我们观察到,两种知识转移方法都表现出测试集误差,与局部模型相比,当两个模型时,四,或新产品的八个实验用于培训。随后,我们解决的问题是否可以通过利用现有知识更有效地设计新产品的实验。特别是,我们建议专门为新产品设计一些运行来校准知识转移模型,我们硬币校准设计的任务。我们提出了一个定制的目标函数来识别一组校准设计运行,利用历史产品演变过程中的差异。在两个模拟案例研究中,我们观察到,与普通实验设计相比,使用校准设计进行训练会产生相似的测试集误差.然而,前者需要大约少四倍的实验。总的来说,结果表明,当系统地将知识从一种产品传递到另一种产品时,工艺开发可以显着简化。
    Modern machine learning has the potential to fundamentally change the way bioprocesses are developed. In particular, horizontal knowledge transfer methods, which seek to exploit data from historical processes to facilitate process development for a new product, provide an opportunity to rethink current workflows. In this work, we first assess the potential of two knowledge transfer approaches, meta learning and one-hot encoding, in combination with Gaussian process (GP) models. We compare their performance with GPs trained only on data of the new process, that is, local models. Using simulated mammalian cell culture data, we observe that both knowledge transfer approaches exhibit test set errors that are approximately halved compared to those of the local models when two, four, or eight experiments of the new product are used for training. Subsequently, we address the question whether experiments for a new product could be designed more effectively by exploiting existing knowledge. In particular, we suggest to specifically design a few runs for the novel product to calibrate knowledge transfer models, a task that we coin calibration design. We propose a customized objective function to identify a set of calibration design runs, which exploits differences in the process evolution of historical products. In two simulated case studies, we observed that training with calibration designs yields similar test set errors compared to common design of experiments approaches. However, the former requires approximately four times fewer experiments. Overall, the results suggest that process development could be significantly streamlined when systematically carrying knowledge from one product to the next.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    发酵罐中代谢物控制的自动化是更快,更可靠地开发疫苗生产过程的基础。我们创建了一个端到端过程分析技术(PAT)和质量设计(QbD)集中的过程,通过在补料分批生物过程的开发过程中使用高度适应性的系统取代了代谢物的手动控制,和自动化启用。中红外(MIR)光谱与衰减全反射探头在线,和使用比尔-兰伯特定律的简单线性回归,已开发用于从发酵过程中测量复杂培养基的光谱数据中定量关键代谢物(葡萄糖和谷氨酸)。这些数据以数字方式连接到过程信息管理系统(PIMS),为了使用比例-积分-微分(PID)控制器实现给水泵的连续控制,在整个补料分批搅拌罐发酵罐过程中保持营养水平。来自搅拌釜反应器中培养物的中红外光谱的连续代谢物数据使药物开发实验室的反馈回路和进料泵的控制成为可能。这将营养水平的过程控制提高了20倍,药物的产量提高了一个数量级。此外,该方法适用于其他系统,并实现软传感,如代谢物的消耗率。快速和简单地开发定量代谢物模板以改变生物过程的能力有助于项目加速和提高过程控制和自动化。
    Automation of metabolite control in fermenters is fundamental to develop vaccine manufacturing processes more quickly and robustly. We created an end-to-end process analytical technology and quality by design-focused process by replacing manual control of metabolites during the development of fed-batch bioprocesses with a system that is highly adaptable and automation-enabled. Mid-infrared spectroscopy with an attenuated total reflectance probe in-line, and simple linear regression using the Beer-Lambert Law, were developed to quantitate key metabolites (glucose and glutamate) from spectral data that measured complex media during fermentation. This data was digitally connected to a process information management system, to enable continuous control of feed pumps with proportional-integral-derivative controllers that maintained nutrient levels throughout fed-batch stirred-tank fermenter processes. Continuous metabolite data from mid-infrared spectra of cultures in stirred-tank reactors enabled feedback loops and control of the feed pumps in pharmaceutical development laboratories. This improved process control of nutrient levels by 20-fold and the drug substance yield by an order of magnitude. Furthermore, the method is adaptable to other systems and enables soft sensing, such as the consumption rate of metabolites. The ability to develop quantitative metabolite templates quickly and simply for changing bioprocesses was instrumental for project acceleration and heightened process control and automation.
    UNASSIGNED: Intelligent digital control systems using continuous in-line metabolite data enabled end-to-end automation of fed-batch processes in stirred-tank reactors.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    β-胡萝卜素,维生素A的前体,对健康和营养应用具有重要的前景。这项研究介绍了一种在酿酒酵母中生产β-胡萝卜素的优化方法,利用代谢工程和农业废物的新用途。GAL80基因缺失促进了蔗糖中β-胡萝卜素的高效合成,避免昂贵的半乳糖诱导,效价高达727.8±68.0mg/L,含量为71.8±0.4mg/g细胞干重(DCW)。此外,农副产品的应用,特别是糖蜜和鱼粉作为碳源和氮源,被调查。这种方法产生的β-胡萝卜素滴度为354.9±8.2mg/L,含量为60.5±4.3mg/gDCW,展示了这些可持续基材用于工业规模生产的潜力。这项研究为成本效益设定了新的基准,重要营养素的绿色制造,展示了一个可扩展的,生产β-胡萝卜素的环保替代品。
    β-carotene, a precursor to vitamin A, holds significant promise for health and nutrition applications. This study introduces an optimized approach for β-carotene production in Saccharomyces cerevisiae, leveraging metabolic engineering and a novel use of agricultural waste. The GAL80 gene deletion facilitated efficient β-carotene synthesis from sucrose, avoiding the costly galactose induction, and achieved titers up to 727.8 ± 68.0 mg/L with content levels of 71.8 ± 0.4 mg/g dry cell weight (DCW). Furthermore, the application of agricultural by-products, specifically molasses and fish meal as carbon and nitrogen sources, was investigated. This approach yielded a substantial β-carotene titer of 354.9 ± 8.2 mg/L and a content of 60.5 ± 4.3 mg/g DCW, showcasing the potential of these sustainable substrates for industrial-scale production. This study sets a new benchmark for cost-effective, green manufacturing of vital nutrients, demonstrating a scalable, eco-friendly alternative for β-carotene production.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    宿主细胞蛋白(HCP)是在生物治疗剂制造过程中宿主细胞表达的过程相关杂质,例如单克隆抗体(mAb)。一些具有挑战性的HCP在下游加工过程中逃避清除,并且可以与感兴趣的分子共纯化,这可能会影响产品的稳定性,功效,和安全。因此,HCP含量是监测和量化整个生物过程的关键质量属性。在这里,我们探索了一种基于质谱(MS)的蛋白质组学工具,所有理论碎片离子谱(SWATH)策略的顺序窗口采集,作为传统ELISA的正交方法。SWATH工作流程用于高通量个体HCP识别和定量,支持mAb纯化平台的表征。通过实验研究设计评估了两种抛光树脂的HCP间隙的设计空间。实现了对高风险HCP的绝对定量(达到1.8和4.2ppm的定量限,分别用于HCPA和B),使用HCP特异性合成重标记肽校准曲线。使用平均校准曲线(使用来自不同HCP的标记肽)也可以分析其他HCP。SWATH方法是生物过程开发期间HCP评估的强大工具,能够同时监测和量化不同的个体HCP,并提高对其清除的过程理解。
    Host cell proteins (HCPs) are process-related impurities expressed by the host cells during biotherapeutics\' manufacturing, such as monoclonal antibodies (mAbs). Some challenging HCPs evade clearance during the downstream processing and can be co-purified with the molecule of interest, which may impact product stability, efficacy, and safety. Therefore, HCP content is a critical quality attribute to monitor and quantify across the bioprocess. Here we explored a mass spectrometry (MS)-based proteomics tool, the sequential window acquisition of all theoretical fragment-ion spectra (SWATH) strategy, as an orthogonal method to traditional ELISA. The SWATH workflow was applied for high-throughput individual HCP identification and quantification, supporting characterization of a mAb purification platform. The design space of HCP clearance of two polishing resins was evaluated through a design of experiment study. Absolute quantification of high-risk HCPs was achieved (reaching 1.8 and 4.2 ppm limits of quantification, for HCP A and B respectively) using HCP-specific synthetic heavy labeled peptide calibration curves. Profiling of other HCPs was also possible using an average calibration curve (using labeled peptides from different HCPs). The SWATH approach is a powerful tool for HCP assessment during bioprocess development enabling simultaneous monitoring and quantification of different individual HCPs and improving process understanding of their clearance.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:糖尿病是一种由于胰岛素不足或不敏感而影响全球超过5亿人的疾病。对于1型糖尿病患者,胰岛移植可以帮助调节他们的血糖水平。然而,尸体供体胰岛的稀缺限制了可以接受这种治疗的人数。为了解决这个问题,人多能干细胞为通过定向分化产生胰岛素产生细胞提供了潜在的无限来源.已经开发了几种方案来制备干细胞衍生的胰岛素产生细胞。然而,缺乏关于与这些分化方案相关的生物过程参数以及如何利用它们来增加细胞产量的知识。
    方法:我们研究了各种生物工艺参数和质量目标产品概况,这些参数和质量目标产品概况可能会影响分化管道,使用CellSTACKs和垂直轮式生物反应器(PBS-Minis)以可扩展的方式使用七阶段方案。
    结果:细胞在分化的所有阶段和适当表达的阶段特异性标志物中保持>80%的生存力。在胰腺祖细胞发育的最初四个阶段,细胞数量有所增加。在胰腺祖细胞阶段之后,增殖细胞的百分比逐渐下降,由Ki67阳性确定,以及在内分泌分化期间细胞的显著损失。通过最小化聚集体融合的发生,我们能够在分化的后期提高细胞产量。我们建议,葡萄糖利用和乳酸产生是细胞质量属性,在表征源自干细胞的胰岛素产生细胞时应考虑。我们的发现还揭示了糖酵解的逐渐代谢转变,在胰腺祖细胞形成的最初四个阶段,后来在内分泌分化过程中氧化磷酸化。此外,产生胰岛素的细胞对几种促分泌素有反应,包括高葡萄糖.
    结论:这项研究证明了过程参数,例如葡萄糖消耗和乳酸生产率,这些参数可用于促进干细胞衍生的胰岛素生产细胞的可扩展制造。
    Diabetes is a disease affecting over 500 million people globally due to insulin insufficiency or insensitivity. For individuals with type 1 diabetes, pancreatic islet transplantation can help regulate their blood glucose levels. However, the scarcity of cadaveric donor islets limits the number of people that could receive this therapy. To address this issue, human pluripotent stem cells offer a potentially unlimited source for generating insulin-producing cells through directed differentiation. Several protocols have been developed to make stem cell-derived insulin-producing cells. However, there is a lack of knowledge regarding the bioprocess parameters associated with these differentiation protocols and how they can be utilized to increase the cell yield.
    We investigated various bioprocess parameters and quality target product profiles that may influence the differentiation pipeline using a seven-stage protocol in a scalable manner with CellSTACKs and vertical wheel bioreactors (PBS-Minis).
    Cells maintained > 80% viability through all stages of differentiation and appropriately expressed stage-specific markers. During the initial four stages leading up to the development of pancreatic progenitors, there was an increase in cell numbers. Following pancreatic progenitor stage, there was a gradual decrease in the percentage of proliferative cells, as determined by Ki67 positivity, and a significant loss of cells during the period of endocrine differentiation. By minimizing the occurrence of aggregate fusion, we were able to enhance cell yield during the later stages of differentiation. We suggest that glucose utilization and lactate production are cell quality attributes that should be considered during the characterization of insulin-producing cells derived from stem cells. Our findings also revealed a gradual metabolic shift from glycolysis, during the initial four stages of pancreatic progenitor formation, to oxidative phosphorylation later on during endocrine differentiation. Furthermore, the resulting insulin-producing cells exhibited a response to several secretagogues, including high glucose.
    This study demonstrates process parameters such as glucose consumption and lactate production rates that may be used to facilitate the scalable manufacture of stem cell-derived insulin-producing cells.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    化学定义的矿物介质广泛用于生物过程中,因为与复杂介质相比,这些显示出较少的批次间差异。尽管如此,推荐的培养基配方通常导致在升高的pH值下形成沉淀物。这些沉淀物是不可溶的,并降低了大量营养素对细胞的可用性,这可能导致限制增长率和降低生产率。它们还可以通过堵塞管道损坏设备,软管,和喷雾器在搅拌罐发酵罐。在这项研究中,通过X射线荧光光谱分析观察到的沉淀物,并确定为磷酸镁铵盐鸟粪石(MgNH4PO4×6H2O)。已知鸟粪石晶体的溶解度极低,导致大量营养素镁,磷酸盐,和铵结合在鸟粪石晶体中。这里,结果表明,鸟粪石沉淀物可以在常见的发酵条件下重新溶解。此外,发现鸟粪石粒径分布对溶解动力学有显著影响,直接影响常量营养素的可用性。在一定的粒度下,鸟粪石晶体迅速溶解并提供不受限制的生长条件。因此,在培养基和生物过程开发过程中应考虑鸟粪石的形成,以确保鸟粪石的溶解动力学比生长动力学更快。
    Chemically defined mineral media are widely used in bioprocesses, as these show less batch to batch variation compared with complex media. Nonetheless, the recommended media formulations often lead to the formation of precipitants at elevated pH values. These precipitates are insoluble and reduce the availability of macronutrients to the cells, which can result in limiting growth rates and lower productivity. They can also damage equipment by clogging pipes, hoses, and spargers in stirred tank fermenters. In this study, the observed precipitate was analyzed via X-ray fluorescence spectroscopy and identified as the magnesium ammonium phosphate salt struvite (MgNH4 PO4  × 6H2 O). The solubility of struvite crystals is known to be extremely low, causing the macronutrients magnesium, phosphate, and ammonium to be bound in the struvite crystals. Here, it was shown that struvite precipitates can be redissolved under common fermentation conditions. Furthermore, it was found that the struvite particle size distribution has a significant effect on the dissolution kinetics, which directly affects macronutrient availability. At a certain particle size, struvite crystals rapidly dissolved and provided unlimiting growth conditions. Therefore, struvite formation should be considered during media and bioprocess development, to ensure that the dissolution kinetics of struvite are faster than the growth kinetics.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    疫苗是人类生命不可或缺的一部分,可以保护它们免受危及生命的疾病的侵害。然而,常规疫苗通常会受到低效等限制,安全问题,不可培养的微生物不可用,和病原体之间的遗传变异。嵌合疫苗结合了相似或不同微生物菌株的多个抗原编码基因,以防止过度进化的耐药病原体。可怕疾病的爆发导致研究人员开发出经济的嵌合疫苗,可以在更短的时间内满足大量人群的需求。过程开发始于基于计算辅助的基于组学的方法来设计嵌合疫苗。此外,开发这些疫苗需要优化上游和下游工艺,以实现工业规模的大规模生产。由于不断发展的病原体的复杂结构和复杂的生物加工,各种高通量工艺技术已经提出了额外的优势。高通量工具的最新进展,过程分析技术(PAT),质量按设计(QBD),实验设计(DoE),建模和仿真,一次性使用技术,和集成的连续生物处理使可扩展的生产更加方便和经济。向创新战略的范式转变需要高度重视,以应对全球范围内的重大健康威胁。这篇综述概述了嵌合疫苗生物过程开发中的挑战和新兴途径。
    Vaccines are integral to human life to protect them from life-threatening diseases. However, conventional vaccines often suffer limitations like inefficiency, safety concerns, unavailability for non-culturable microbes, and genetic variability among pathogens. Chimeric vaccines combine multiple antigen-encoding genes of similar or different microbial strains to protect against hyper-evolving drug-resistant pathogens. The outbreaks of dreadful diseases have led researchers to develop economical chimeric vaccines that can cater to a large population in a shorter time. The process development begins with computationally aided omics-based approaches to design chimeric vaccines. Furthermore, developing these vaccines requires optimizing upstream and downstream processes for mass production at an industrial scale. Owing to the complex structures and complicated bioprocessing of evolving pathogens, various high-throughput process technologies have come up with added advantages. Recent advancements in high-throughput tools, process analytical technology (PAT), quality-by-design (QbD), design of experiments (DoE), modeling and simulations, single-use technology, and integrated continuous bioprocessing have made scalable production more convenient and economical. The paradigm shift to innovative strategies requires significant attention to deal with major health threats at the global scale. This review outlines the challenges and emerging avenues in the bioprocess development of chimeric vaccines.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    拉曼光谱广泛用于监测和控制生物制药药物制造的细胞培养。然而,其在细胞系发育阶段的培养监测中的实施很少受到关注。因此,克隆差异的影响,比如生产力和增长,拉曼校准模型的预测准确性和可转移性尚未得到很好的描述。在这项研究中,我们开发了拉曼OPLS模型来预测滴度,使用来自单个细胞系的11个CHO克隆的葡萄糖和乳酸。这些克隆表现出不同的生产力和生长速率。我们使用交叉验证预测的克隆线性回归分析评估了克隆相关偏差的校准模型。结果表明,克隆差异不影响葡萄糖和乳酸的预测,但是滴度模型显示出明显的克隆相关偏倚,即使在应用变量选择方法后仍然存在。偏差与克隆生产力有关,并在将滴度模型转移到生产力水平超出其训练数据范围的培养物时,会导致预测误差增加。我们的发现证明了基于拉曼的葡萄糖和乳酸在细胞系开发中高精度监测的可行性。然而,准确的滴度预测需要在模型开发过程中仔细考虑克隆特性。本文受版权保护。保留所有权利。
    Raman spectroscopy is widely used in monitoring and controlling cell cultivations for biopharmaceutical drug manufacturing. However, its implementation for culture monitoring in the cell line development stage has received little attention. Therefore, the impact of clonal differences, such as productivity and growth, on the prediction accuracy and transferability of Raman calibration models is not yet well described. Raman OPLS models were developed for predicting titer, glucose and lactate using eleven CHO clones from a single cell line. These clones exhibited diverse productivity and growth rates. The calibration models were evaluated for clone-related biases using clone-wise linear regression analysis on cross validated predictions. The results revealed that clonal differences did not affect the prediction of glucose and lactate, but titer models showed a significant clone-related bias, which remained even after applying variable selection methods. The bias was associated with clonal productivity and lead to increased prediction errors when titer models were transferred to cultivations with productivity levels outside the range of their training data. The findings demonstrate the feasibility of Raman-based monitoring of glucose and lactate in cell line development with high accuracy. However, accurate titer prediction requires careful consideration of clonal characteristics during model development.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    生物制药行业面临着最大限度提高效率的压力,提高质量合规性,并降低原料药制造成本。降低与制造复杂生物分子相关的成本的方法包括使色谱纯化步骤的效率最大化。例如,过程分析技术工具可用于提高柱树脂寿命,防止色谱柱操作故障,并减少解决过程偏差调查所需的时间。我们开发了一种强大的方法来探测色谱图的形状,以指示色谱柱故障或过程中的有害变化。本文的方法利用从制造获得的原始数据,随后是预处理例程,以将色谱图对齐并将不同的色谱相拼贴在一起,为多变量分析做准备。对标准化色谱图进行主成分分析,比较不同批次,并导致影响配置文件的识别特定过程更改。此外,色谱峰的变化用于创建杂质清除的预测模型.这种方法有可能早期发现色谱柱处理问题,提高大规模色谱操作中的及时分辨率。本文受版权保护。保留所有权利。
    The biopharmaceutical industry is under increased pressure to maximize efficiency, enhance quality compliance, and reduce the cost of drug substance manufacturing. Ways to reduce costs associated with manufacturing of complex biological molecules include maximizing efficiency of chromatography purification steps. For example, process analytical technology (PAT) tools can be employed to improve column resin life, prevent column operating failures, and decrease the time it takes to solve investigations of process deviations. We developed a robust method to probe the shape of the chromatogram for indications of column failure or detrimental changes in the process. The approach herein utilizes raw data obtained from manufacturing followed by a pre-processing routine to align chromatograms and patch together the different chromatogram phases in preparation for multivariate analysis. A principal component analysis (PCA) was performed on the standardized chromatograms to compare different batches, and resulted in the identification specific process change that affected the profile. In addition, changes in the chromatogram peaks were used to create predictive models for impurity clearance. This approach has the potential for early detection of column processing issues, improving timely resolution in large-scale chromatographic operations.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号